相关实验视频
Updated: Sep 18, 2025

05:07
Microwave-Assisted Preparation of 1-Aryl-1H-pyrazole-5-amines
Published on: June 23, 2019
6.8K
作为多目标抗阿尔茨海默氏症剂的皮拉佐洛皮里丁含化合物:合成,生物评估和在研究中
Omnia M Waly1,2, Selwan M El-Sayed1,3, Mariam A Ghaly1
1Department of Medicinal Chemistry, Faculty of Pharmacy, Mansoura University, Mansoura, Egypt.
Archiv der Pharmazie
|June 22, 2025
概括
新的基于pyrazolopyridine的多目标定向联结体 (MTDLs) 通过抑制关键的病理途径,对阿尔茨海默病 (AD) 治疗有希望. 化合物15和23显示出显著的活性和安全性,表明潜在的治疗应用.
科学领域:
- 药用化学 医学化学
- 神经科学是一个神经科学.
- 药物设计 药物设计
背景情况:
- 阿尔茨海默病 (AD) 是一种复杂的神经退行性疾病,具有多种促成因素.
- 目前的治疗方法效果有限,需要新的治疗策略,如多目标定向连接体 (MTDL).
研究的目的:
- 为阿尔茨海默病设计和合成基于pyrazolopyridine的新型MTDL.
- 评估这些化合物抑制AD关键病理特征的潜力,包括胆酶酶,粉样β聚合,高酸化和金属诱导的氧化损伤.
主要方法:
- 设计和合成三系列的pyrazolopyridine衍生物.
- 在体外评估酶抑制 (胆化酶,GSK3β).
- 对粉样β聚合抑制的评估.
- 生物金属化研究.
- 代谢稳定性评估 (化合物31作为23的代谢物).
- 细胞毒性测试 (WI-38细胞系).
- 在 silico 血脑屏障透预测.
主要成果:
- 化合物15和23有效抑制胆酶,防止Aβ聚合,并向GSK3β.
- 皮拉佐洛皮里丁核心有助于结合到目标部位.
- 化合物31是23的代谢物,也表现出MTDL特性,表明长时间的作用.
- 化合物15和23显示出良好的安全性和良好的药理动力学特性 (利宾斯基法则,BBB透).
结论:
- 设计的基于pyrazolopyridine的MTDL是阿尔茨海默病治疗的有希望的候选人.
- 化合物15和23代表具有多目标抑制潜力的化合物,并具有有利的安全性.
- 需要进一步的研究,以在临床前的AD模型中探索它们的治疗疗效.
更多相关视频
相关概念视频
Alzheimer's Disease: Treatment
265
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
265
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
214
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
214
Antidepressant Drugs: MAOIs and Other Agents
378
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
378
Drugs Affecting Neurotransmitter Synthesis
1.6K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.6K
Parkinson's Disease: Treatment
391
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
391
Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
668
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
668

